NGS also detected a heterozygous missense variant in SMARCA4 (c.3484G > A, p.Gly1162Ser) in the tumor DNA with a VAF of 56%, affecting the C-terminal helicase domain of the protein. This evidence concerns the gene SMARCA4 and neoplasm.